Exelixis
EXEL
#1305
Rank
A$24.46 B
Marketcap
A$98.75
Share price
4.82%
Change (1 day)
66.34%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): A$4.86

According to Exelixis's latest financial reports the company's current EPS (TTM) is A$4.70. In 2025 the company made an earnings per share (EPS) of A$4.11.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$4.8618.24%
2025A$4.11
2023A$0.9314.61%
2022A$0.81-22.97%
2021A$1.05100%
2020A$0.53-65.09%
2019A$1.51-53.91%
2018A$3.27333.96%
2017A$0.75-260.61%
2016A-$0.47-58.75%
2015A-$1.14-42.45%
2014A-$1.985.3%
2013A-$1.88

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
A$12.43 164.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$1.08-76.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$23.08 391.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$2.71-42.34%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$1.80-61.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$6.46 37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$4.55-3.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
A-$20.24-530.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
A-$1.20-125.45%๐Ÿ‡บ๐Ÿ‡ธ USA